Indoco’s posts Rs 1604.8 million revenue during the fourth quarter of FY 2012-13

By On May 29, 2013

Indoco Remedies has recorded revenues at Rs 1604.8 million during the fourth quarter of FY 2012-13 as compared to Rs 1476.6 million over the same quarter last year. The un-audited results for the fourth quarter of the financial year 2012-13 were announced by the Board of Directors of Indoco Remedies at their recently held meeting in Mumbai.

Earnings before interest, taxes, depreciation, and amortization (EBIDTA) was reported at Rs 282.2 million and Profit After Tax (PAT) at Rs 128.5 million during fourth quarter ended March 2013 of FY 2012-13. The consolidated EBIDTA for the year stood at Rs 1061.6 million, operating profit at Rs 605.6 million and PAT at Rs 427.2 million.

Suresh G Kare, Executive Chairman said, “I am glad that the domestic formulation sales in the fourth quarter surpassed the industry average growth rate. The much awaited Drug Pricing Policy has now been announced and the impact on the company is marginal. The business from the US is expected to ramp up with a few ANDAs slated for approval thereby giving boost to the international business revenues. Going forward, the company will accelerate sales growth with improved margins.”

EP News Bureau- Mumbai